Funding led by Neue Fund and BioVentures Investors to extend pathology AI research and allow strategic life science and AI investors into the round.
SALT LAKE CITY, December 16, 2020—PathologyWatch has announced $2M in extension funding from Neue Fund, BioVentures GmbH, Lateral Capital, BeniVC and Sky Ventures. PathologyWatch will direct the capital towards digital dermatopathology development and scaling the laboratory system to extend pathology AI research and to allow additional strategic life science and AI investors into the round.
Following $5M series A funding, the $2M extension brings the total capital PathologyWatch has raised to $7M series A. The company has raised over $10M total capital to date. The extension funds will bolster operations to facilitate larger clients and continue progress in developing innovative technology, including the extension of artificial intelligence research for various cancer lines.
“It’s thrilling to see our year-over-year volume triple,” said Dan Lambert, Pathlogywatch CEO and cofounder. “With that increase comes the demand to improve algorithms, build out operational volume, increase lab capacity and augment staffing to ensure our clients achieve optimal patient outcomes.”
PathologyWatch specializes in providing dermatology clinics with fully interfaced EMR reporting and 24/7 access to digital slides. In addition to more efficient workflows and faster turnaround times, clients have direct access to leading dermatopathologists.
“In the digital dermatopathology universe, PathologyWatch stands apart with cutting-edge technology and services designed to improve the human experience,” noted Cofield Mundi of Neue Fund. “Our confidence couldn’t be higher in their ingenuity and devotion to advancing the digital dermatopathology landscape.”
About PathologyWatch
PathologyWatch is the groundbreaking leader of digital dermatopathology services. Through these services, dermatology clinics, hospitals and laboratories can improve operational efficiency by speeding up workflow and enhancing patient outcomes by utilizing the PathologyWatch expert professional team and partner laboratory services. This can facilitate best-in-class reads and, in some cases, enable additional revenue to the practice by in-housing pathology. With an intuitive and easy-to-implement digital pathology solution that includes access to top-tier dermatopathologists and a streamlined clinical workflow that interfaces directly into the EMR, PathologyWatch brilliantly combines state-of-the-art technology and clinical decision-making to deliver unprecedented patient care.
View the original release.